Considering that IL-6 and IFN-γ play a significant role in the pathogenesis of AMD, and that both AD and AMD share a number of striking similarities [35], such results corroborate our hypothesis that the anti-TNFSF10 antibody treatment represents a valuable strategy for the management of sight-threatening retinal degenerative diseases. This evidence concerns the gene TNFSF10 and Alzheimer disease.